Nuvectis Pharma Stock Today
| NVCT Stock | USD 4.90 0.17 3.35% |
Performance0 of 100
| Odds Of DistressOver 61
|
Nuvectis Pharma is selling for under 4.90 as of the 22nd of November 2024; that is 3.35 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 4.68. Nuvectis Pharma has more than 61 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Nuvectis Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of February 2022 | Category Healthcare | Classification Health Care |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey. Nuvectis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 19.32 M outstanding shares of which 1.13 M shares are now shorted by private and institutional investors with about 7.94 trading days to cover. More on Nuvectis Pharma
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Nuvectis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Nuvectis Pharma (NVCT) is traded on NASDAQ Exchange in USA. It is located in 1 Bridge Plaza, Fort Lee, NJ, United States, 07024 and employs 13 people. Nuvectis Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 97.96 M. Nuvectis Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 19.32 M outstanding shares of which 1.13 M shares are now shorted by private and institutional investors with about 7.94 trading days to cover.
Nuvectis Pharma currently holds about 13.57 M in cash with (15.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93.
Check Nuvectis Pharma Probability Of Bankruptcy
Ownership AllocationNuvectis Pharma maintains a total of 19.32 Million outstanding shares. Nuvectis Pharma holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Nuvectis Ownership Details
Nuvectis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Edmond De Rothschild Holding S.a. | 2024-06-30 | 19.2 K | |
| Jane Street Group Llc | 2024-06-30 | 17 K | |
| Renaissance Technologies Corp | 2024-09-30 | 15.8 K | |
| State Street Corp | 2024-06-30 | 15.3 K | |
| Northern Trust Corp | 2024-09-30 | 15.3 K | |
| Citadel Advisors Llc | 2024-06-30 | 14.9 K | |
| Jpmorgan Chase & Co | 2024-06-30 | 14.8 K | |
| Hrt Financial Llc | 2024-06-30 | 13.6 K | |
| Centiva Capital Lp | 2024-06-30 | 13.3 K | |
| Vanguard Group Inc | 2024-09-30 | 301.1 K | |
| Baldwin Brothers Inc | 2024-06-30 | 168.6 K |
Nuvectis Pharma Historical Income Statement
Nuvectis Stock Against Markets
Nuvectis Pharma Corporate Executives
Elected by the shareholders, the Nuvectis Pharma's board of directors comprises two types of representatives: Nuvectis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nuvectis. The board's role is to monitor Nuvectis Pharma's management team and ensure that shareholders' interests are well served. Nuvectis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nuvectis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shay Shemesh | Executive CoFounder | Profile | |
| Enrique Poradosu | Executive CoFounder | Profile |
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.